MMMichele Mahone

Michele Mahone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michele Mahone has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Florence Weber

    Centre Hospitalier de l'Universite de Montreal, Montreal, QC

    4 shared publications
  • Andre Masse

    Department of Gynecology and Obstetrics, Centre Hospitalier de l’Université de Montréal, Université de Montréal, 1000 St-Denis, Montreal, QC H2X 0C1, Canada

    2 shared publications
  • Christian Watier

    Department of Medicine, Centre Hospitalier de l’Université de Montréal, Université de Montréal, 1000 St-Denis, Montreal, QC H2X 0C1, Canada

    2 shared publications
  • Denis Soulières

    Department of Medicine, Service of Hemato‐Oncology Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal Montreal Quebec Canada

    2 shared publications
  • Florence Weber

    Department of Medicine, Centre Hospitalier de l’Université de Montréal, Université de Montréal, 1000 St-Denis, Montreal, QC H2X 0C1, Canada

    2 shared publications
  • Laurence Blain

    Department of Medicine, Centre Hospitalier de l’Université de Montréal, Université de Montréal, 1000 St-Denis, Montreal, QC H2X 0C1, Canada

    2 shared publications

Latest Publications

  • Acute fatty liver in pregnancy presenting in the second trimester: A systematic literature review

    by Laurence Bourque, Michèle Mahone

    Objective: We present clinical features and outcomes of second-trimester acute fatty liver of pregnancy (AFLP), a serious but rare condition. Results: Fourteen pregnant women with AFLP or compatible biopsy were identified in the literature. Diagnosis occurred between 20 and 27 + 6 weeks of gestational age. In total, 50% were primigravid. Thirteen cases met the Swansea criteria while the other case had a compatible liver biopsy. In total, 10 out of 11 cases had microvesicular steatosis on their liver biopsy. Common maternal complications included acute renal failure, hypoglycaemia, liver failure, encephalopathy, intensive care unit admission and need for blood transfusions. Seven deliveries were on the day of diagnosis, five within four weeks, and two within three months. One maternal death, seven fetal deaths and three neonatal deaths occurred. Conclusion: AFLP diagnosed in the second trimester is a rare condition. Neonatal mortality and maternal morbidity are high. Most cases had nonspecific symptoms and clinical findings, but a majority had compatible biopsies.


  • Prediction of obstetric outcomes in sickle cell patients based on tricuspid regurgitant velocity

    by Audrey Lacasse, Vincent Williams, Pallavi Ganguli, Sophie Grand’mAison, Bilan Wo, Veronique Cyr, Marie-Lou Tardif, Nadia Caron, Julien Viau-Lapointe, Veronique Naessens, et al.

    Background: Transthoracic echocardiography, a validated tool for risk assessment in non-pregnant population with sickle cell disease (SCD), uses tricuspid regurgitant velocity (TRV) over 2.5 m/s is an independent mortality risk factor. Its applicability in obstetrics lacks sufficient evidence. Methods: In this multicenter retrospective cohort study across five tertiary centers, we aimed to validate TRV as a determinant of increased maternal and fetal risk. Data was collected on 93 women and included 21 patients with TRV of at least 2.5 m/s. The maternal primary composite outcome included occurrence of vaso-occlusive crisis, acute chest syndrome, gestational hypertension, preeclampsia, and mortality. The fetal primary composite outcome comprised perinatal mortality, premature delivery, reduced birth weight, and fetal distress. Results: Adverse maternal and fetal events arose in both groups with no statistical difference. Conclusion: This study cannot support TRV of 2.5 m/s or more as an independent predictor of adverse obstetric outcomes among women with SCD.

  • Open Access

    Anti-synthetase syndrome diagnosed during pregnancy: a case report and literature review

    by A Mourot, M Mahone, H Manganas, J Bourré-Tessier, O Landon-Cardinal


  • Open Access

    Prospective Evaluation of Fetal Hemoglobin Expression in Maternal Erythrocytes: An Analysis of a Cohort of 345 Parturients

    by Laurence Blain, Christian Watier, Xiaoduan Weng, Andre Masse, Marie-Josée Bédard, Nazila Bettache, Florence Weber, Michele Mahone, Stéphanie Forté, Vincent-Philippe Lavallée, et al.

    It is believed that fetal hemoglobin (HbF) expression in adults is largely genetically regulated. The increased expression of HbF in pregnancy has been reported in a small number of articles. Different mechanisms have been proposed, but the description of HbF expression during pregnancy remains unclear. The objectives of this study were to document HbF expression during peri and postpartum periods, confirm its maternal origin, and assess clinical and biochemical parameters potentially associated with HbF modulation. In this observational prospective study, 345 pregnant women were followed. At baseline, 169 had HbF expression (≥1% of total hemoglobin) and 176 did not have HbF expression. Women were followed at the obstetric clinic during their pregnancy. Clinical and biochemical parameters were measured at each visit. Analyses were made to determine which parameters had a significant correlation to HbF expression. Results show that HbF expression of ≥1% during peri and postpartum periods in pregnant women without influencing comorbidities is at its highest peak during the first trimester. In all women, it was proven that HbF was of maternal origin. A significant positive correlation between HbF expression, βeta-human chorionic gonadotropin (β-HCG), and glycosylated hemoglobin (HbA1c) was present. A significant negative association between HbF expression and total hemoglobin was found. HbF expression induction during pregnancy is probably associated with an increase in β-HCG and HbA1C, and a decrease in total hemoglobin, which could temporarily reactivate the fetal erythropoietic system.


  • Open Access

    Prospective Evaluation of Fetal Hemoglobin Expression in Maternal Erythrocytes: an Analysis of a Cohort of 345 Parturients

    by Laurence Blain, Christian Watier, Xiaoduan Weng, Andre Masse, Marie-Josée Bédard, Nazila Bettache, Florence Weber, Michele Mahone, Stéphanie Forte, Vincent-Philippe Lavallée, et al.

    It is believed that fetal hemoglobin (HbF) expression in adults is largely genetically regulated. The increased expression of HbF in pregnancy has been reported in a small number of articles. Different mechanisms have been proposed, but the description of HbF expression during pregnancy remains unclear. The objectives of this study were to document HbF expression during peri and postpartum periods, confirm its maternal origin, and assess clinical and biochemical parameters potentially associated with HbF modulation. In this observational prospective study, 345 pregnant women were followed. At baseline, 169 had HbF expression (≥1% of total hemoglobin) and 176 did not have HbF expression. Women were followed at the obstetric clinic during their pregnancy. Clinical and biochemical parameters were measured at each visit. Analyses were made to determine which parameters had a significant correlation to HbF expression. Results show that HbF expression of ≥ 1% during peri and postpartum periods in pregnant women without influencing comorbidities is at its highest peak during the first trimester. In all women, it was proven that HbF was of maternal origin. A significant positive correlation between HbF expression, β-HCG, and HbA1C was present. A significant negative association between HbF expression and total hemoglobin was found. HbF expression induction during pregnancy is probably associated with increase in β-HCG and HbA1C, and decrease of total hemoglobin, which could temporarily reactivate the fetal erythropoietic system.

  • Transient Hypertensive Effect in Pregnancy: A Pragmatic Pilot Study

    by Audrey Lacasse, Karine Dahl, Bi Lan Wo, Florence Weber, Tal Kopel, Nazila Bettache, Michele Mahone

  • Evaluation of Complications in Postpartum Women Receiving Therapeutic Anticoagulation

    by Gabrielle Md Côté-Poirier, Nazila Md Bettache, Anne-Marie Md Côté, Michèle Md Mahone, Francine Morin, Annabelle Cumyn, Yves-André Bureau, Mandy Malick, Nadine Md Sauvé

    OBJECTIVE: To evaluate complications associated with early postpartum therapeutic anticoagulation. METHODS: A multicenter retrospective cohort study was done to evaluate the association between therapeutic anticoagulation postpartum and major complications (hemorrhagic and wound complications). Secondary outcomes included minor complications, risk factors associated with total complications (including the time to therapeutic anticoagulation resumption after delivery) and recurrent thrombotic events within 6 weeks postpartum. RESULTS: From 2003 to 2015, 232 consecutive women were treated with therapeutic anticoagulation within 96 hours postpartum; among those treated, 91 received unfractionated heparin, 138 received low-molecular-weight heparin, and three received other anticoagulants. The primary outcome, a composite of major hemorrhagic complications (requiring transfusion, hospitalization, volume resuscitation, transfer to intensive care unit, or surgery) and major wound complications, occurred in 7 of 83 (8.4%) for cesarean deliveries and 9 of 149 (6.0%) for vaginal deliveries (P=.490). Total complications (including major and minor hemorrhagic and wound complications) occurred in 13 of 83 (15.7%) for cesarean deliveries compared with 9 of 149 (6.0%) for vaginal deliveries (P=.016). When comparing cases associated with and without complications, the median delay before resuming anticoagulation was significantly shorter for both cesarean (12 vs 33 hours, P=.033) and vaginal deliveries (6 vs 19 hours, P=.006). For vaginal deliveries, 8 of 51 (15.7%) women had complications when anticoagulation was started before 9.25 hours postpartum, compared with 1 of 98 (1.0%) when started after 9.25 hours. For cesarean deliveries, 7 of 21 (33.3%) of women experienced complications compared with 6 of 62 (9.7%) if anticoagulation was started before or after 15.1 hours, respectively. Two (0.9%) episodes of venous thromboembolism occurred within 6 weeks postpartum. CONCLUSION: Among postpartum women who received early therapeutic anticoagulation, major complications occurred in 8.4% for cesarean deliveries and 6.0% for vaginal deliveries. Complications were associated with earlier resumption of therapeutic anticoagulation, particularly before 9.25 hours for vaginal deliveries and before 15.1 hours for cesarean deliveries.


  • Mixed connective tissue disease in pregnancy: A case series and systematic literature review

    by Marie-Lou Tardif, Michèle Mahone

    Objective: To investigate the impact of medical and obstetric complications associated with mixed connective tissue disease (MCTD) in pregnancy. Method: We analyzed 68 pregnancies from a systematic literature review and 12 pregnancies affected by MCTD at our centre between 1986 and 2015 for medical and obstetric complications. Results: During pregnancy 37.1% had active MCTD and 26.7% had relapsed. Maternal complications included caesarean section (31.1%, n = 19), preeclampsia (17.6%, n = 13), thromboembolism events, and death (2.5%, n = 2 for each). Fetal complications included prematurity (48.1%, n = 25), intrauterine growth restriction (38.3%, n = 19), and neonatal lupus (28.6%, n = 18, including chondrodysplasia punctata). More than half ( n = 10) of the neonatal lupus cases were explained by anti-U 1 RNP only. The perinatal mortality rate was 17.7% ( n = 14). Pregnant women with active disease had higher rates of prematurity (OR = 7.60; 95%CI [1.93; 29.95]) and perinatal death (OR = 16.83; 95%CI [1.90; 147.70]). Conclusion: MCTD in pregnancy puts women at risk of medical and obstetric complications, and disease activity probably increases this risk.


  • Henoch-Schonlein purpura in pregnancy: A case report

    by Jean-Maxime Côté, Rosalie-Sélène Meunier, Jan-Alexis Tremblay, Florence Weber, Michèle Mahone

    Henoch-Schonlein purpura is a relatively common pediatric vasculitis. Very few cases of Henoch-Schonlein purpura during pregnancy have been described. Henoch-Schonlein purpura is variable in its presentation, from completely benign to possibly catastrophic complications. This rarely encountered condition in adults can also be a recurrence of a previous childhood disease. We present a case of a pregnant 40-year-old woman with Henoch-Schonlein purpura, resulting in a viable birth with no fetal complications. Her presentation is discussed in detail and a general presentation of Henoch-Schonlein purpura is explored, with particular attention to its rare onset during pregnancy.


  • A 30-year-old pregnant patient with massive haemoptysis and influenza A: Atypical presentation of a common pathogen

    by Philippe Nguyen, Florence Weber, Michèle Mahone

    A 30-year-old woman presented at 19 weeks of gestation with symptoms of sore throat, rhinorrhea and haemoptysis that progressed to massive haemoptysis. Her medical history included asthma and a history of smoking prior to pregnancy. Investigations revealed no obvious cause of bleeding. Right lower lobe lobectomy was performed, given the suspicion of a lesion within the intermediate bronchus. The patient developed adult respiratory distress syndrome around 36 h postoperatively. Polymerase chain reaction testing on bronchoalveolar lavage samples was positive for influenza A. Therapy with oseltamivir was initiated. She was discharged two weeks later. This is a rare case of a severe complication from seasonal interpandemic influenza during pregnancy, which underscores the importance of immunization for pregnant women.